Basilea Pharmaceutica Valuation
| BPMUF Stock | USD 52.83 0.00 0.00% |
At this time, the firm appears to be overvalued. Basilea Pharmaceutica shows a prevailing Real Value of $48.6 per share. The current price of the firm is $52.83. Our model approximates the value of Basilea Pharmaceutica from analyzing the firm fundamentals such as Shares Outstanding of 11.93 M, return on asset of 0.0261, and Operating Margin of 0.06 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Basilea Pharmaceutica's price fluctuation is very steady at this time. Calculation of the real value of Basilea Pharmaceutica is based on 3 months time horizon. Increasing Basilea Pharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Basilea pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Basilea Pharmaceutica AG. Since Basilea Pharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Basilea Pink Sheet. However, Basilea Pharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 52.83 | Real 48.6 | Hype 52.83 | Naive 52.83 |
The real value of Basilea Pink Sheet, also known as its intrinsic value, is the underlying worth of Basilea Pharmaceutica Company, which is reflected in its stock price. It is based on Basilea Pharmaceutica's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Basilea Pharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Basilea Pharmaceutica AG helps investors to forecast how Basilea pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Basilea Pharmaceutica more accurately as focusing exclusively on Basilea Pharmaceutica's fundamentals will not take into account other important factors: Basilea Pharmaceutica Total Value Analysis
Basilea Pharmaceutica AG is currently anticipated to have takeover price of 724.26 M with market capitalization of 626.06 M, debt of 94.54 M, and cash on hands of 140.74 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Basilea Pharmaceutica fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
724.26 M | 626.06 M | 94.54 M | 140.74 M |
Basilea Pharmaceutica Investor Information
About 29.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings (P/E) ratio of 200.0. Basilea Pharmaceutica had not issued any dividends in recent years. Based on the key measurements obtained from Basilea Pharmaceutica's financial statements, Basilea Pharmaceutica AG is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Basilea Pharmaceutica Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Basilea Pharmaceutica has an asset utilization ratio of 59.9 percent. This implies that the Company is making $0.6 for each dollar of assets. An increasing asset utilization means that Basilea Pharmaceutica AG is more efficient with each dollar of assets it utilizes for everyday operations.Basilea Pharmaceutica Ownership Allocation
The market capitalization of Basilea Pharmaceutica is $626.06 Million. Basilea Pharmaceutica AG shows 3.07 percent of its outstanding shares held by insiders and 29.13 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Basilea Pharmaceutica Profitability Analysis
The company reported the revenue of 148.12 M. Net Loss for the year was (6.83 M) with profit before overhead, payroll, taxes, and interest of 30.89 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Basilea Pharmaceutica's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Basilea Pharmaceutica and how it compares across the competition.
About Basilea Pharmaceutica Valuation
The pink sheet valuation mechanism determines Basilea Pharmaceutica's current worth on a weekly basis. Our valuation model uses a comparative analysis of Basilea Pharmaceutica. We calculate exposure to Basilea Pharmaceutica's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Basilea Pharmaceutica's related companies.Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland. BASILEA PHARMACEUTICA is traded on OTC Exchange in the United States.
8 Steps to conduct Basilea Pharmaceutica's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Basilea Pharmaceutica's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Basilea Pharmaceutica's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Basilea Pharmaceutica's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Basilea Pharmaceutica's revenue streams: Identify Basilea Pharmaceutica's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Basilea Pharmaceutica's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Basilea Pharmaceutica's growth potential: Evaluate Basilea Pharmaceutica's management, business model, and growth potential.
- Determine Basilea Pharmaceutica's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Basilea Pharmaceutica's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Basilea Pharmaceutica Growth Indicators
Investing in growth stocks can be very risky. If the company such as Basilea Pharmaceutica does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 11.8 M | |
| Forward Price Earnings | 104.1667 | |
| Retained Earnings | -1 B |
Complementary Tools for Basilea Pink Sheet analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |